efineptakin alfa + pembrolizumab + cyclophosphamide

A combination therapy consisting of **efineptakin alfa** (an IL-7 cytokine-based immunotherapy), **pembrolizumab** (an anti–PD-1 monoclonal antibody), and **cyclophosphamide** (an alkylating chemotherapeutic agent). **Pembrolizumab** restores anticancer immune function by inhibiting the PD-1 receptor on T-cells, **cyclophosphamide** suppresses regulatory T cells and has direct cytotoxic anticancer effects, and **efineptakin alfa** is designed to stimulate T-cell proliferation and function. This triple therapy is under clinical investigation for cancer immunotherapy, particularly in solid tumors such as ovarian cancer and advanced malignancies.

Other names

MSD 3475 (for pembrolizumab)NSC 26271 (for cyclophosphamide)